Clinical trials: Adalimumab
Ulcerative Colitis
A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to assess the efficacy and safety of adalimumab in Japanese subjects with moderately to severely active ulcerative colitis (UC).
- Trial name
- NCT00853099
- Testing
- adalimumab
- Where
- 65 sites in Japan
- Volunteers
- 274 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Intestinal Behcet's Disease (BD)
A Prospective, Mono-Country and Multi-center Study to Observe Safety and Effectiveness of Adalimumab in KoREan Intestinal Behcet's Disease(BD) Patients
This study evaluates the safety profile and effectiveness of adalimumab in Korean intestinal Behcet's disease (BD) patients in routine clinical practice.
- Trial name
- AMORE (NCT02687828)
- Where
- 10 sites in South Korea
- Volunteers
- 59 people
- Sponsor
- AbbVie
Hidradenitis Suppurativa (HS)
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
A study to evaluate the safety and efficacy of treatment with adalimumab in adults with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- PIONEER I (NCT01468207)
- Testing
- adalimumab
- Volunteers
- 307 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Ankylosing Spondylitis
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
The current study will assess the real - life effectiveness of adalimumab in the management of Ankylosing Spondylitis (AS) with emphasis on the prevention and management of extra-articular manifestations.
- Trial name
- Complete-AS (NCT01387802)
- Where
- 56 sites in Canada
- Volunteers
- 722 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Bioequivalence, Phase 1
A Study Of CinnoRA (Adalimumab-CinnaGen) And Adalimumab (Humira) In Healthy Subjects
This study aims to demonstrate pharmacokinetic (PK) similarity of biosimilar candidate CinnoRA® relative to adalimumab reference product (Humira®) and evaluate safety and tolerability of CinnoRA®, in a parallel fashion in healthy…
- Trial name
- NCT03273192
- Testing
- Adalimumab
- Where
- Iran
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Cinnagen
Sarcoidosis
Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis
The purpose of the study is to see if Humira is effective and safe in the treatment of sarcoidosis.
- Trial name
- NCT00690911
- Testing
- adalimumab
- Where
- United States
- Sponsor
- Wake Forest University
Erosive Osteo-Arthritis
Study to Evaluate the Efficacy of Adalimumab in Patients With Erosive Osteoarthritis of the Interphalangeal Finger Joints
Patients will be randomized into two groups (1/1) during one year: 40 mg adalimumab subcutaneously (sc) every other week placebo The effect on x-rays and clinical parameters will be evaluated.
- Trial name
- NCT00296894
- Testing
- Adalimumab (40 mg sc every other week)
- Where
- Belgium
- Volunteers
- 60 people
- Sponsor
- University Hospital, Ghent
Rheumatoid Arthritis
Comparison of Adalimumab and Infliximab Treatment of Rheumatoid Arthritis
The purpose of this study is to establish whether RA patients with moderate to severe disease activity with unsustainable response to infliximab 3 mg/kg every 8 weeks have better efficacy with adalimumab 40 mg s.c.
- Trial name
- NCT00216177
- Testing
- Infliximab, Adalimumab
- Where
- 6 sites in Denmark
- Volunteers
- 112 people
- Sponsor
- Hvidovre University Hospital
Osteoarthritis
A Pilot Trial of Adalimumab for the Treatment of Osteoarthritis
A 12 week trial of Adalimumab in subjects with active erosive inflammatory OA who have ahd an inadequate response to NSAID therapy
- Trial name
- NCT00185562
- Testing
- Adalimumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stanford University
Crohn's Disease
A Study of Subcutaneous HUMIRA (Adalimumab) Injection to Assess Adverse Events and Change in Disease Activity In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will assess how safe and effective Humira (adalimumab) is in treating moderately to severely active CD in China.
- Trial name
- NCT05394805
- Where
- 10 sites in China
- Volunteers
- 156 people
- Sponsor
- AbbVie
Ankylosing Spondylitis
A Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis
To evaluate efficacy, safety and pharmacokinetics of adalimumab in Japanese subjects with active ankylosing spondylitis
- Trial name
- NCT00667355
- Testing
- adalimumab
- Where
- 19 sites in Japan
- Volunteers
- 41 people
- Sponsor
- Abbott
Crohn's Disease
Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
The purpose of this study is to evaluate the safety of adalimumab for treatment of patients with moderate to severe Crohn's Disease (CD) and to measure the effects of treatment on patient general well-being, health-related…
- Trial name
- NCT00409617
- Testing
- adalimumab
- Where
- 189 sites in Austria, Belgium and 15 more
- Volunteers
- 945 people
- Sponsor
- Abbott
Uveitis, Diabetic Retinopathy
Intravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot Study
Direct intravitreal administration of medication is the preferred method of treatment for uveitis and retinal vascular disorders.
- Conditions
- Uveitis, Diabetic Retinopathy, Choroidal Neovascularization
- Trial name
- ADA01 (NCT00855608)
- Testing
- adalimumab
- Where
- Lebanon
- Volunteers
- 15 people
- Sponsor
- Rafic Hariri University Hospital
Crohn's Disease
Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.
A substantial fraction of IBD patients with an initial response to infliximab or adalimumab later experience re-emerging active disease despite ongoing anti-Tumour Necrosis Factor (TNF) agents maintenance therapy.
- Trial name
- VEDIAN (NCT06180382)
- Testing
- Adalimumab, Vedolizumab
- Where
- 12 sites in France
- Volunteers
- 220 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Inflammatory Bowel Diseases
Biomarkers of Anti-TNF Treatment in Inflammatory Bowel Disease (IBD)
Anti-TNF treatment (infliximab (IFX), adalimumab (ADA)) has become standard therapy for refractory pediatric and adult Crohn's disease (CD) patients, and is used for the induction (primary response) and maintenance of remission.
- Trial name
- NCT01971970
- Testing
- Infliximab, Adalimumab
- Where
- Netherlands
- Volunteers
- 45 people
- Sponsor
- Erasmus Medical Center
Psoriasis
Swiss Dermatology Network of Targeted Therapies (SDNTT)
The purpose of this study is to evaluate the long-term course of patients with psoriasis and psoriatic-arthritis in systemic treatments such as, methotrexate, cyclosporin A, fumaric acids, acitretin, systemic PUVA, etanercept…
- Trial name
- SDNTT (NCT01706692)
- Testing
- Adalimumab, Etanercept, Infliximab
- Where
- 6 sites in Switzerland
- Volunteers
- 1,121 people
- Sponsor
- Swiss Dermatology Network for Targeted Therapies
Rheumatoid Arthritis
A 3-year Study Following up Patients With Moderate to Severe Rheumatoid Arthritis Treated With Humira in Greece
The objectives of the study are to observe and assess the long-term use, safety and efficacy of Humira (adalimumab), as prescribed by the rheumatologist in a normal clinical setting and in accordance with the terms of the…
- Trial name
- NCT01086033
- Where
- 60 sites in Greece
- Volunteers
- 566 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Crohn's Disease
Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease
To evaluate the long-term maintenance of response, safety and tolerability of repeated administration of adalimumab in subjects with Crohn's disease who participated in and successfully completed Protocol M02-404 or Protocol…
- Trial name
- NCT00195715
- Testing
- Adalimumab
- Where
- 111 sites in United States, Australia and 13 more
- Volunteers
- 777 people
- Sponsor
- Abbott
Psoriatic Arthritis
Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)
The purpose of the study is to assess the safety and clinical efficacy of adalimumab in active psoriatic arthritis (PsA) subjects when adalimumab is added to insufficient standard therapy including patients that have failed other…
- Trial name
- STEREO (NCT00235885)
- Testing
- adalimumab
- Where
- United States
- Volunteers
- 445 people
- Sponsor
- Abbott
Psoriasis
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
A Phase III, Multicenter Study of the Efficacy and Safety of Adalimumab Treatment in Subjects with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- NCT00237887
- Testing
- adalimumab
- Volunteers
- 1,212 people
- Sponsor
- Abbott